Key result
Cilostazol reduces stroke recurrence without increasing major bleeding but causes ~6% more side-effect discontinuations.
Why the study?
Prior trials supporting cilostazol for secondary stroke prevention in Asia had limitations—including open-label design, premature termination, loss to follow-up, and lack of functional outcomes—preventing guideline adoption in Western countries.
Does cilostazol reduce stroke recurrence in patients with noncardioembolic stroke?
Does cilostazol reduce stroke recurrence in patients with noncardioembolic stroke?
While cilostazol reduces stroke recurrence in Asian populations with noncardioembolic stroke, its adoption in Western guidelines requires confirmation through broader, double-blind, placebo-controlled trials.
No takes yet. Share an insight, caveat, or question.
Supports cilostazol in Asian noncardioembolic stroke; leaves open Western adoption pending confirmatory RCTs.
Havenon et al. (2021) studied this question. Cilostazol reduced stroke recurrence and is safe, without increasing major bleeding risk, but caused a 6% higher discontinuation rate due to side effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: